New long-term data for Uplizna (inebilizumab-cdon) from open-label extension of N-MOmentum trial in patients with neuromyelitis optica spectrum disorder (NMOSD)

Long-term treatment was reported to provide sustained reduction in NMOSD attack risk from baseline, with 87.7% patients who originally received inebilizumab (n=165) and 83.4% who originally received placebo (n=51) remaining attack-free during open label phase for at least 4 years

SPS commentary:

This phase 2/3 clinical trial consisted of a 28-week randomised controlled period, where study participants received inebilizumab or placebo. Following completion of this period, patients could enter into open label phase for at least two years, during which all patients (n=216) received inebilizumab 300mg every six months.

Inebilizumab is an anti-CD19 B-cell depleting humanised monoclonal antibody that is hs been approved in US specifically for the treatment of adult patients who are anti-aquaporin-4 antibody positive. A regulatory submission was filed in EU in Jan 2021.

Biospace Inc.